NCT00072384
Clinical Trial Information
Trial Number: NCT00072384 (ClinicalTrials.gov)
Disease Type:
- Eye Neoplasm - Retinoblastoma
Trial Title:
A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma
Study ID:
ARET0231
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00072384-D5 | NCT00072384 - D5 Dataset Description: NCT00072384 – D5 is one of 5 data submissions associated with PubMed ID 32589362. This dataset provides the information for delays in treatment. It is used to generate data reported at the end of Section 3.5, Systemic Toxicity. |
| NCT00072384-D4 | NCT00072384 - D4 Dataset Description: NCT00072384 – D4 is one of 5 data submissions associated with PubMed ID 32589362. This dataset provides the information for the specific toxicities that occurred during protocol therapy. There is one row per patient/toxicity term. |
| NCT00072384-D3 | NCT00072384 - D3 Dataset Description: NCT00072384 – D3 is one of 5 data submissions associated with PubMed ID 32589362. This dataset provides the information of the primary outcome data, i.e. whether event occurred within 1 year since enrollment along with other details. There is one row for each eye. It is used to generate a summary of patient presentation and failure event (Table 3) and the information at the end of Section 3 Results. |
| NCT00072384-D2 | NCT00072384 - D2 Dataset Description: NCT00072384 – D2 is one of 5 data submissions associated with PubMed ID 32589362. This dataset provides detailed eye-level local therapy information for each cycle. It is used to generate Ophthalmology treatment details for the 29 Group C/D eyes (Table 2). |
| NCT00072384-D1 | NCT00072384 - D1 Dataset Description: NCT00072384 - D1 is one of 5 data submissions associated with PubMed ID 32589362. This dataset provides the information for patients who were enrolled on ARET0231. There is one row for each patient enrolled. The dataset provides the information of baseline characteristics, eye stage from local and central review, outcome data and ocular toxicity on ARET0231 as reported in the manuscript. It is used to generate the Summary of Baseline Characteristics for eligible patients (Table 1), and the information in the beginning of Section 3 Results, Section 3.2 Patterns of intraocular recurrence, Section 3.3 Extraocular recurrence/deaths, and Section 3.4 Ocular toxicity. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®